These are the results of a study that evaluated adults with HER2-negative, high-risk early breast cancer with an inherited BRCA mutation. Women and men in the study had surgery and received chemotherapy either before or after their surgery. Patients with hormone receptor–positive breast cancer may have also received hormonal therapy.

In this study, 921 adults were treated with LYNPARZA and 915 were treated with placebo.

PATIENTS WERE TREATED FOR UP TO 1 YEAR,

unless they experienced significant side effects or their cancer returned.

Your healthcare provider will decide how long you stay on treatment with LYNPARZA.

LYNPARZA helped prevent breast cancer from returning in more patients compared with placebo.

42%

Lower risk of cancer returning

LYNPARZA reduced the risk of cancer returning by 42% in early breast cancer compared with placebo.

This means that there was a lower chance of breast cancer returning, new cancers growing, or death compared with placebo.

815 out of 921 patients treated with LYNPARZA did not have their breast cancer return, new cancers grow, and were alive compared with 737 out of 915 patients treated with placebo.

LYNPARZA helped more patients live longer compared with placebo.

32%

Lower risk of death

LYNPARZA lowered the risk of death by 32% in early breast cancer compared with placebo.

In this study, 846 out of 921 patients treated with LYNPARZA were alive at the time of follow-up as compared with 806 out of 915 treated with placebo.

These data are a secondary conclusion, or result, of the overall study.